What did UBS change about its rating for ELAN on March 10, 2026?

UBS did not change the rating; it **maintained a Buy** on ELAN on **March 10, 2026**. The note described 2026 as catalyst-rich but did not publish a new price target in the StreetInsider summary.

How should investors read a maintained Buy in the ELAN analyst rating?

A maintained Buy signals continued analyst confidence, not a fresh upgrade. Investors should weigh the rating with company results, product timelines, and other analyst notes before changing exposure.

Did UBS publish an ELAN price target with the March 10, 2026 note?

No. The StreetInsider summary of UBS’s March 10, 2026 note did not include an updated ELAN price target. Investors should watch for full reports or follow-up notes for target updates.

What is Meyka AI’s view alongside the ELAN analyst rating?

Meyka AI rates ELAN **B+**, combining benchmark comparison, sector performance, growth, metrics, and analyst consensus. This complements the UBS maintained Buy but is not investment advice.

Analyst Ratings

UBS maintains Buy on ELAN (Elanco Animal Health Incorporated) March 2026

ByHuzaifa Zahoor March 11, 2026March 11, 2026

UBS maintained a Buy on Elanco Animal Health Incorporated (ELAN) on March 10, 2026. This ELAN analyst rating reflects UBS’s view that the company’s 2026 catalysts will support revenue and margin progress. UBS described the outlook as “catalyst-rich,” and the research note carried no new price at time data but noted a short-term stock move. The UBS action coincided with a -2.37% ($-0.57) intraday change reported at the same update. Investors should weigh the maintained Buy against recent share volatility and company fundamentals.